Prognostic Significance of C-Reactive Protein in Lenvatinib-Treated Unresectable Hepatocellular Carcinoma: A Multi-Institutional Study.
Taiki OkumuraTakefumi KimuraTakanobu IwadareShun-Ichi WakabayashiHiroyuki KobayashiYuki YamashitaAyumi SugiuraSatoru JoshitaNaoyuki FujimoriHideo KunimotoMichiharu KomatsuHideki FukushimaHiromitsu MoriTakeji UmemuraPublished in: Cancers (2023)
A baseline serum CRP level exceeding 0.5 mg/dL was identified as an unfavorable prognostic factor in HCC patients receiving lenvatinib treatment.